Suchergebnisse - "Xu, Binghe"

PubPharm (520)

41

A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments

enthalten in: International journal of cancer | 2023

von Xu, B. | Ma, F. | Wang, T. | +15

42

OlympiAD extended follow-up for overall survival and safety : Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Robson, M. | Im, S. | Senkus, E. | +10

43

Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study)

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Wang, J. | Cai, L. | Song, Y. | +13

44

Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors

enthalten in: Investigational new drugs | 2023

von Luo, Y. | Cheng, Y. | Wu, C. | +5

45

Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors

enthalten in: Investigational new drugs | 2023

von Luo, Y. | Cheng, Y. | Wu, C. | +5

46

Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors

enthalten in: Investigational new drugs | 2023

von Luo, Y. | Cheng, Y. | Wu, C. | +5

47

Combined chemo-endocrine therapy as a potential new option for HR+/HER2- advanced breast cancer : a prospective study of fulvestrant plus oral vinorelbine

enthalten in: Cancer biology & medicine | 2023

von Wang, X. | Yue, J. | Kang, Y. | +7

48

Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer : A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial

enthalten in: Acta pharmaceutica Sinica. B | 2023

von Xu, B. | Zhang, Q. | Hu, X. | +24

49

PRR15 deficiency facilitates malignant progression by mediating PI3K/Akt signaling and predicts clinical prognosis in triple-negative rather than non-triple-negative breast cancer

enthalten in: Cell death & disease | 2023

von Guo, F. | Ma, J. | Li, C. | +12

50

High BRCA1 expression is an independent prognostic biomarker in LUAD and correlates with immune infiltration

enthalten in: Cancer innovation | 2023

von Guo, F. | Li, C. | Liu, S. | +4